Some clinical observations on the treatment with L-asparaginase of the acute leukemias.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D001792:Blood Platelets / Q000032:analysis; D001831:Body Temperature; D001856:Bone Marrow Examination; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D004906:Erythrocyte Count; D004926:Escherichia coli / Q000201:enzymology; D005340:Fibrinogen / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007958:Leukocyte Count; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D014527:Uric Acid / Q000652:urine
D006454:Hemoglobins; D014527:Uric Acid; D005340:Fibrinogen; D001215:Asparaginase